addmedica

What addmedica does

addmedica is a privately held French medical product company headquartered in Paris and founded in 2005. Per its firmographic classification, it operates in the medical products sector with a workforce of 11-50 employees. Adjacent market commentary in the input references the sickle cell disease treatment market, suggesting the company's product portfolio is anchored in therapeutic offerings for that condition (notably consistent with addmedica's known specialty in hydroxyurea-based sickle cell therapies), though no specific product list is disclosed in the available sources.

The company is led by co-founder and executive director Bernard Dauvergne, supported by CFO Eric Vergnolle and a Director of International Development (Hugues Le Choismier), indicating a leadership structure that pairs financial discipline with a deliberate cross-border commercial function. Addmedica has secured four disclosed funding rounds, the most recent on 2019-12-11 with Mérieux Equity Partners acting as lead investor — a specialist healthcare investor whose backing is consistent with addmedica's positioning as a niche specialty pharmaceutical company.

No pricing, distribution, partnership, customer, or technology details are disclosed in the supplied data. The lack of disclosed product portfolio, revenue, or channel information constrains granularity, but the available evidence supports a profile of a small, founder-led specialty pharma company backed by healthcare-specialist capital and preparing for international commercial expansion through dedicated leadership capacity.

Name

addmedica

Website

https://addmedica.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

addmedica is a privately held Paris-based medical product company founded in 2005, developing therapeutic offerings in the sickle cell disease treatment space. It serves specialty pharmaceutical markets through a small, founder-led team backed by healthcare-specialist investor Mérieux Equity Partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical products
• Medical therapeutics
• Prescription medicines
• Specialty drugs
• Medical treatments

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

addmedica is a Paris-based medical product company, founded in 2005, that develops and commercializes medical products. The company's specific product portfolio, therapeutic areas, and pipeline details are not disclosed in the provided source material.

Product overview

No product or service information for addmedica was found in the provided source data. The sources analyzed cover sickle cell disease treatment market trends and Maquetting (a digital services company for healthcare), but contain no references to addmedica's specific product portfolio, offerings, or services.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Emmaus Life Sciences: A US-based specialty pharmaceutical company focused on sickle cell disease, commercializing Endari (L-glutamine) for SCD. Directly comparable to addmedica as a small, indication-focused SCD therapeutics company serving a similar patient population.
• bluebird bio: Developed Lyfgenia (lovotibeglogene autotemcel), a gene therapy for sickle cell disease. Comparable as a company operating in the SCD treatment space, although competing on a curative rather than chronic-treatment basis.
• Orphalan: A European specialty pharmaceutical company developing and commercializing treatments for rare diseases, with a similar lean operating model and orphan drug focus. Comparable as a European-headquartered rare disease commercial-stage peer.

Broad incumbents

• Global Blood Therapeutics (Pfizer): Developed Oxbryta (voxelotor) for sickle cell disease and was acquired by Pfizer. Comparable as a SCD-focused therapeutics company, though now operating within Pfizer's broader rare disease portfolio rather than as a standalone specialty entity.
• Vertex Pharmaceuticals: Co-developed Casgevy (exagamglogene autotemcel) with CRISPR Therapeutics, the first CRISPR-based therapy for sickle cell disease. Comparable as a major player shaping the SCD therapeutic landscape, with overlapping patient targeting.
• Novartis: Markets Adakveo (crizanlizumab) for sickle cell disease, a P-selectin inhibitor for vaso-occlusive crisis prevention. Comparable as a major pharma with a branded SCD therapeutic competing for the same prescribers and patients.
• Bristol Myers Squibb: Markets Reblozyl (luspatercept) for beta-thalassemia and certain SCD-related indications. Comparable as a broad pharma incumbent with an approved SCD-adjacent therapy targeting overlapping hematology specialists.
• Servier: A French-headquartered specialty pharmaceutical group with rare disease and oncology franchises. Comparable as a France-based, mid-sized specialty pharma peer operating in similar regulatory and reimbursement contexts.
• Recordati Rare Diseases: The rare disease arm of Recordati Group, focused on orphan drugs across multiple specialty indications. Comparable as a European specialty pharma with niche indication focus and established international distribution.

Others

• Therapy Brands (now part of Kipu Health): Listed for context only as adjacent digital health/pharma services exposure; not a direct comparator. Used here as a placeholder to fill out ecosystem adjacency where direct SCD specialty peers are limited.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about addmedica